CASI — CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Q2 2022 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: CASI reported $8.6 million in revenue from EVOMELA sales for Q2 2022, a 19% increase from $7.2 million in Q2 2021. However, this was a slight decline from $9 million in Q1 2022 due to COVID-related lockdowns in major Chinese cities.
• Cost of Revenues: Increased to $3.6 million from $3 million year-over-year, including royalty payments of $1.7 million.
• Cash Position: The company ended the quarter with $18.9 million in cash and cash equivalents.
• Financing: CASI secured a revolving line of credit up to $10 million for working capital purposes.

2. Strategic Updates and Business Highlights:

• Product Launches: CASI is preparing for the anticipated launch of CNCT19, a CAR-T product, in China, with an NDA filing expected in the second half of 2022.
• Pipeline Development:
  • BI-1206 is expected to start Phase 1 trials soon, with CTA approval anticipated during 2022.
  • CID-103 is currently in a Phase 1 study in Europe.
  • A sub-license agreement with Precision Autoimmune Therapeutics was established, granting them rights to develop an anti-CD38 monoclonal antibody for autoimmune diseases, providing CASI with a $10 million upfront payment.
• EVOMELA: Continues to be a key product, with a focus on expanding its use in hematology-oncology.

3. Forward Guidance and Outlook:

• CASI aims to leverage its existing commercial infrastructure to support the launch of CNCT19 and continue to drive revenue growth from EVOMELA.
• The company is optimistic about its pipeline and expects to meet several key milestones in the upcoming quarters.

4. Challenges and Points of Concern:

• COVID-19 Impact: Ongoing lockdowns in China have created unpredictability in revenue generation, particularly affecting sales in major cities like Shanghai.
• Market Competition: There is a growing number of CAR-T therapies being developed in China, which may increase competitive pressures once CNCT19 is launched.
• Financial Health: While the company is well-financed into 2023, the current capital market conditions are challenging.

5. Notable Q&A Insights:

• Management acknowledged the unpredictability of COVID-19 policies in China and their potential impact on sales forecasts.
• The partnership with Precision Autoimmune Therapeutics was chosen to allow CASI to focus on hematology-oncology while still exploring opportunities in autoimmune diseases.
• There is confidence in the manufacturing capacity for CNCT19, with sufficient capacity for at least 1,000 patients in the first year post-approval.
• The timeline for BI-1206 and Thiotepa development was discussed, with expectations for submissions and feedback from regulatory bodies within the next few months.

Overall, CASI Pharmaceuticals is navigating a challenging environment but remains focused on advancing its product pipeline and maintaining revenue growth from its existing products.